Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (3): 292-295.
DOI: 10.19803/j.1672-8629.2022.03.13

Previous Articles     Next Articles

A analysis of safety of 73 users of carrelizumab

HUANG Can1, QI Lamei1, LI Duohui1, CHEN Zhaolin2,#, JU Jing3,*   

  1. 1Department of Pharmacy Management, Affiliated Anqing Hospital of Anhui Medical University, Anqing Anhui 246000, China;
    2Department of Pharmacy, the First Affiliated Hospital of University of Science and Technology of China, Hefei Anhui 230001, China;
    3Department of Equipment, Affiliated Anqing Hospital of Anhui Medical University, Anqing Anhui 246000, China
  • Received:2021-06-07 Online:2022-03-15 Published:2022-03-16

Abstract: Objective To retrospectively analyze the safety of carrelizumab in clinical use among cancer patients and to provide reference for rational use of this drug. Methods The clinical data on inpatients who had received carrilizumab in the Affiliated Anqing Hospital of Anhui Medical University between January 1 and December 31, 2020 was collected. The basic information on these patients, medications and the incidence of immune-related adverse events (irAEs) were recorded and analyzed to evaluate the safety of clinical medication. The relationships between irAEs and gender, age, preexisting diseases and cancer types were explored. Results Carrelizumab was used by seventy-three tumor patients for 264 times, and forty-one of these patients experienced off-label drug use. irAEs occurred in thirty-nine of these patients, six of whom had adverse reactions involving three or more systems. Among the cases of adverse reactions, twenty-nine were of grade 1~2 toxicity, nine of grade 3 toxicity, and one of grade 4 toxicity, including endocrine toxicity, skin and mucosal toxicity and liver toxicity. The incidence of irAEs varied according to types of tumors, being the highest with liver cancer and the lowest with lung cancer, and the difference was statistically significant. Conclusion The off-label drug use of carrelizumab is common. The incidence of irAEs is high, but symptoms are not severe. Early detection and interventions are of great importance.

Key words: tumor, carrelizumab, off-label drug use, adverse drug reactions, safety

CLC Number: